IPA EU Position


Over the last 20 years, there have been more than 7,500 studies published on probiotics, according to PubMed. In 2015, there were more than 1,000 publications of articles in scientific journals outlining their health benefits.

Articles have appeared in peer review scientific journals of the highest quality such as The Lancet, European Journal of Clinical Nutrition, Clinical Infectious Diseases, Gastroenterology and the British Medical Journal.

Resiliance as a valid measure of helth and the implications for health benefits of specific foods and food ingredients

In a recent ISAPP blog, scientists explored the concept of ‘resilience’ in the context of human physiology, i.e. the ability to remain healthy even when exposed to a stress, or to recover from a stress faster, and concluded that the recent recognition by EFSA that maintenance of homeostasis is a valid measure of health provides an opportunity to apply this concept to specific foods and food ingredients.

Download the Press Release

Download the full text of the ISAPP blog


A scientific paper published in European Journal of Public Health reports that those who take probiotics as a preventative measure are less likely to receive antibiotic prescriptions

The systematic review, which was authored by an international group of ten scientists, reviewed studies that administered Lactobacillus or Bifidobacterium to healthy people to determine the impact of probiotics on incidence or duration of common infectious diseases. In all studies that also tracked antibiotic use, the study found that healthy infants and children who consumed probiotics rather than a placebo were at least 29% less likely to receive or consume antibiotics. No studies in adults were included because these studies did not track antibiotic prescriptions.

Link to the pdf paper


IPA Europe comments on the EFSA draft scientific and technical guidance

IPA Europe appreciates the opportunity provided by EFSA to comment on the revised draft guidelines for the preparation and presentation of a health claim application. IPA Europe continues to request the possibility of having a dialogue between the applicant and EFSA prior to the submission of a dossier.


IPA Europe comments on the revised EFSA guidance documents

On 18 January, the European Food Safety Authority (EFSA) published the revised guidance for health claims related to the immune system, the gastrointestinal tract and defence against pathogenic microorganisms  and also the general scientific guidance on health claim applications. IPA Europe is happy to see that these documents clarify some questions and that the consultation procedure has therefore been productive. However, there are also still a number of points that IPA Europe believes have not been adequately considered.
Read more


The Clinical and Economic Impact of Probiotics Consumption on Respiratory Tract Infections: Projections for Canada

The aim of this study was to assess the impact of probiotic use in terms of number of RTI episodes and days averted, and the number of antibiotic prescriptions and missed workdays averted, in the general population of Canada. In addition, the corresponding economic impact from both a healthcare payer and a productivity perspective was estimated.
Read more

The science of ferments, fermentation, the microbiota & the health of yogurt

This paper, published by Danone, describes the vision of two extraordinary men: Elias Metchnikoff, the first person to observe the health benefits of microorganisms and Isaac Carasso, who was later inspired by the work of Elias Metchnikoff and subsequently founded Danone in order to produce a delicious food with health benefits.

Read more


Probiotic consumption makes economic sense

A recently published study has calculated the economic impact of probiotic consumption (Lenoir-Wijnkoop et al., 2015). This study was sponsored by the Global Alliance for Probiotics (GAP) that have recently joined forces with the Yogurt and Live fermented milks Association (YLFA) and the International Probiotic Organization (IPA) to form IPA Europe.

Read more

Probiotics, prebiotics and the gut microbiota

The purpose of the monograph is to discuss in understandable terms the current abundant scientific knowledge on prebiotics, probiotics and the intestinal microbiota, including the resulting effects on the host. The monograph does not address the detailed regulatory aspects of the topic. The challenge in nutritional sciences is not to tackle disease with a pharmaceutical approach, but rather to maintain and support health and thereby reduce the risk of disease.

Read more

Potential economic impact of probiotics in respiratory tract infections

Click here to download a summary of this study

Public health and budget impact of probiotics on common respiratory tract

Two recent meta-analyses by the York Health Economics Consortium (YHEC) and Cochrane demonstrated probiotic efficacy in reducing the duration and number of common respiratory tract infections (CRTI) and associated antibiotic prescriptions. A health-economic analysis was undertaken to estimate the public health and budget consequences of a generalized probiotic consumption in France.

Read more

Gut microbiota, probiotics and their impact throughout the lifespan

A major symposium hosted in Boston at the Harvard Medical School looked at “Gut Microbiota, Probiotics and Their Impact Throughout the Lifespan”. Leading researchers from around the world were convened to discuss current and emerging science in four areas of the age spectrum (Pregnancy, Neonatal Period, Adult Period, Older Adults). This Executive Proceedings provides a brief view of the topics covered in each of these areas.

Read more

The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic

An expert panel was convened in October 2013 by the International Scientific Association for Probiotics and Prebiotics (ISAPP) to discuss the field of probiotics. This document represents the conclusions of the ISAPP consensus meeting on the appropriate use and scope of the term probiotic.

Read more


The potential for emerging therapeutic options for Clostridium difficile infection

The potential for emerging treatment options and efficacy of anti-C. difficile vaccines are discussed in this review.

Read more

22 – 28 avenue d’Auderghem
1040 Brussels


    +32 2 549 50 81



© 2019 ipaeurope.org - All rights reserved